Advances in Chronic Kidney Disease
Volume 16, Issue 1 , Pages 5-10 , January 2009

Economics and Cost of Care of Stone Disease

  • Yair Lotan

      Affiliations

    • Corresponding Author InformationAddress correspondence to Yair Lotan, MD, Department of Urology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9110.

References 

  1. Cowan CA, Lazenby HC, Martin AB, et al. National health expenditures. Health Care Financ Rev. 1998;21:165–2101999
  2. Chandhoke PS. Economics of urolithiasis: cost-effectiveness of therapies. Curr Opin Urol. 2001;11:391–393
  3. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63:1817–1823
  4. Ljunghall S. Incidence of upper urinary tract stones. Miner Electrolyte Metab. 1987;13:220–227
  5. Saigal CS, Joyce G, Timilsina AR. Direct and indirect costs of nephrolithiasis in an employed population: Opportunity for disease management?. Kidney Int. 2005;68:1808–1814
  6. Pearle MS, Calhoun EA, Curhan GC. Urologic diseases in America project: urolithiasis. J Urol. 2005;173:848–857
  7. Clark JY, Thompson IM, Optenberg SA. Economic impact of urolithiasis in the United States. J Urol. 1995;154:2020–2024
  8. Secker-Walker RH, Vacek PM, Hooper GJ, et al. Screening for breast cancer: time, travel, and out-of-pocket expenses. J Natl Cancer Inst. 1999;91:702–708
  9. Lotan Y, Cadeddu JA, Roehrborn CG, et al. The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. J Urol. 2004;172:1958–1962
  10. O'Leary MP, Baum NH, Blizzard R, et al. 2001 American Urological Association Gallup Survey: Changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction. J Urol. 2002;168:649–652
  11. Escarce JJ. Effects of lower surgical fees on the use of physician services under Medicare. JAMA. 1993;269:2513–2518
  12. Morris DS, Taub DA, Wei JT, et al. Regionalization of percutaneous nephrolithotomy: Evidence for the increasing burden of care on tertiary centers. J Urol. 2006;176:242–246
  13. Landman J, Lee DI, Lee C, et al. Evaluation of overall costs of currently available small flexible ureteroscopes. Urology. 2003;62:218–222
  14. Lotan Y, Gettman MT, Roehrborn CG, et al. Management of ureteral calculi: A cost comparison and decision making analysis. J Urol. 2002;167:1621–1629
  15. Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: A meta-analysis. Lancet. 2006;368:1171–1179
  16. Bensalah K, Pearle M, Lotan Y. Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones. Eur Urol. 2008;53:411–419
  17. Meschi T, Schianchi T, Ridolo E, et al. Body weight, diet and water intake in preventing stone disease. Urol Int. 2004;72(suppl 1):29–33
  18. Curhan GC. Epidemiology of stone disease. Urol Clin North Am. 2007;34:287–293
  19. Curhan GC, Willett WC, Rimm EB, et al. Body size and risk of kidney stones. J Am Soc Nephrol. 1998;9:1645–1652
  20. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723–1727
  21. Goldfarb S. Dietary factors in the pathogenesis and prophylaxis of calcium nephrolithiasis. Kidney Int. 1988;34:544–555
  22. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 2001;59:270–276
  23. Muldowney FP, Freaney R, Moloney MF. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int. 1982;22:292–296
  24. Lemann J, Gray RW, Maierhofer WJ, Cheung HS. The importance of renal net acid excretion as a determinant of fasting urinary calcium excretion. Kidney Int. 1986;29:743–746
  25. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002;346:77–84
  26. Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5-year randomized prospective study. J Urol. 1996;155:839–843
  27. Pearle MS, Roehrborn CG, Pak CY. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol. 1999;13:679–685
  28. Parks JH, Coe FL. The financial effects of kidney stone prevention. Kidney Int. 1996;50:1706–1712
  29. Lotan Y, Cadeddu JA, Roerhborn CG, et al. Cost-effectiveness of medical management strategies for nephrolithiasis. J Urol. 2004;172:2275–2281
  30. Hofbauer J, Hobarth K, Szabo N, et al. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis—A prospective randomized study. Br J Urol. 1994;73:362–365
  31. Ettinger B, Citron JT, Livermore B, et al. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol. 1988;139:679–684

PII: S1548-5595(08)00166-3

doi: 10.1053/j.ackd.2008.10.002

Advances in Chronic Kidney Disease
Volume 16, Issue 1 , Pages 5-10 , January 2009

Article Tools